Prof. Dr. Fatih Demirkan

Thrombotic Events and Overall Survival in BCR-ABL1 Negative Myeloproliferative Neoplasms: A Single-Center Analysis

Konuralp Tip Dergisi, 2026

DOI 10.18521/ktd.1838654 Açık erişimli tam metinKaynak: ORCID

Prognostic Significance of Paraproteinemia in Marginal Zone Lymphoma

Turkish journal of haematology : official journal of Turkish Society of Haematology, 2026

DOI 10.4274/tjh.galenos.2025.2025.0174 PMID 40891517 Açık erişimli tam metinKaynak: Europe PMC

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18–65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network

The Lancet, 2026

DOI 10.1016/s0140-6736(26)00362-4 PMID 42134356 11 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

Molecular Characterization of RhD Variants in the Turkish Population: A Multicenter Study for Population-Specific Diagnostic Strategy Development

Research Square, 2026

DOI 10.21203/rs.3.rs-8630300/v1 Açık erişimli tam metinKaynak: OpenAlex

Refractory Thrombocytopenia in TP53—Aberrant Chronic Lymphocytic Leukemia: A Multimechanistic Case with Response to Idelalisib and Romiplostim

Journal of Clinical Medicine, 2026

DOI 10.3390/jcm15124483 PMID 42355651 Açık erişimli tam metinKaynak: OpenAlex

Clinical Characteristics, Treatment Approaches, and Survival Predictors in Adult Acute Myeloid Leukemia: Interim Results from the Turkish Society of Hematology AML Registry

Journal of Clinical Medicine, 2025

DOI 10.3390/jcm14207367 PMID 41156238 Açık erişimli tam metinKaynak: OpenAlex

AML-556: Personalized Therapy and Real-World Outcomes in Adult Acute Myeloid Leukemia: Lessons From a Nationwide Prospective Cohort in Turkey

Clinical Lymphoma Myeloma & Leukemia, 2025

DOI 10.1016/s2152-2650(25)01691-x Kaynak: OpenAlex

POSTER: AML-556 Personalized Therapy and Real-World Outcomes in Adult Acute Myeloid Leukemia: Lessons From a Nationwide Prospective Cohort in Turkey

Clinical Lymphoma Myeloma & Leukemia, 2025

DOI 10.1016/s2152-2650(25)00540-3 Kaynak: OpenAlex

Therapeutic Plasma Exchange Experience in Internal Medicine Clinics: a Retrospective Review of 1,048 Procedures

SN Comprehensive Clinical Medicine, 2025

DOI 10.1007/s42399-025-02228-0 Açık erişimli tam metinKaynak: ORCID

The Contributions of Turkish Hematology to the Global Literature: A Comparative Analysis

Turkish journal of haematology : official journal of Turkish Society of Haematology, 2025

DOI 10.4274/tjh.galenos.2025.2025.0029 PMID 40353344 Açık erişimli tam metinKaynak: Europe PMC

Comprehensive analysis of FLT3-mutated patients with acute myeloid leukemia with updated 2022 European LeukemiaNet recommendations: insights from the Turkish AML registry project

BMC cancer, 2025

DOI 10.1186/s12885-025-14987-z PMID 41073967 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: Europe PMC

Clinical Manifestations, Treatment Characteristics, and Clinical Outcomes in Patients with Immune Thrombotic Thrombocytopenic Purpura (iTTP) in a Real-World Setting: An Interim Analysis of the Turkish iTTP Registry

Turkish journal of haematology : official journal of Turkish Society of Haematology, 2025

DOI 10.4274/tjh.galenos.2025.2025.0134 PMID 40699136 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: Europe PMC

Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study

Haematologica, 2025

DOI 10.3324/haematol.2024.286091 PMID 39882642 5 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

134 | EFFICACY AND SAFETY OF FIRST‐LINE IBRUTINIB PLUS VENETOCLAX IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO WERE OLDER OR HAD TP53 MUTATIONS IN THE SYMPATICO STUDY

Hematological Oncology, 2025

DOI 10.1002/hon.70093_134 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study.

Journal of Clinical Oncology, 2025

DOI 10.1200/jco.2025.43.16_suppl.7017 3 atıf (OpenAlex) Kaynak: OpenAlex

Comparing two different doses of inotuzumab ozogamicin treatment in adult patients with acute lymphoblastic leukemia: a plain language summary of publication

Therapeutic Advances in Medical Oncology, 2025

DOI 10.1177/17588359251370948 PMID 41084727 Açık erişimli tam metinKaynak: OpenAlex

The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey

Leukemia & lymphoma, 2024

DOI 10.1080/10428194.2023.2280886 PMID 37966980 6 atıf (Europe PMC) Açık erişimli tam metinKaynak: Europe PMC

Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

Infection, 2024

DOI 10.1007/s15010-023-02169-7 PMID 38388854 8 atıf (Europe PMC) Açık erişimli tam metinKaynak: Europe PMC

Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

eClinicalMedicine, 2024

DOI 10.1016/j.eclinm.2024.102553 PMID 38533127 38 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry

Haematologica, 2024

DOI 10.3324/haematol.2023.284678 PMID 38572549 11 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry

Hematological Oncology, 2024

DOI 10.1002/hon.3240 PMID 38050405 16 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial

The Lancet Oncology, 2024

DOI 10.1016/s1470-2045(24)00070-6 PMID 38467131 49 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

Acute Myeloid Leukemia in Elderly, Unfit Patients: Analysis of Turkish AML Prospective Registry Database, on Behalf of Acute Leukemia Working Group of Turkish Society of Hematology

Blood, 2023

DOI 10.1182/blood-2023-189714 2 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

Prospective Real-World Outcomes of Acute Myeloid Leukemia

Blood, 2023

DOI 10.1182/blood-2023-182800 Açık erişimli tam metinKaynak: OpenAlex

A Study of Changes in Prohepcidin and Iron Levels in Patients with Liver Transplant and Chronic Viral Hepatitis

Namık Kemal Tıp Dergisi, 2023

DOI 10.4274/nkmj.galenos.2023.02411 Açık erişimli tam metinKaynak: ORCID

The effect of haemoglobin, albumin, lymphocyte and platelet score on the prognosis in patients with multiple myeloma

International Journal of Laboratory Hematology, 2023

DOI 10.1111/ijlh.13958 PMID 36053932 20 atıf (Europe PMC) Kaynak: ORCID

Idarubicin Versus Daunorubicin Versus Mitoxantrone for Induction Chemotherapy in Acute Myeloid Leukemia: Patient Registration Study of Turkish Society of Hematology-Acute Myeloid Leukemia Working Group

Blood, 2023

DOI 10.1182/blood-2023-187351 3 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

Clinical Outcomes of CNS Lymphoma Treated with Ibrutinib-Based Therapy: A Real-Life Multicenter Experience on Off-Label Use of Ibrutinib

Kocaeli Üniversitesi - AVESİS, 2023

DOI 10.4999/uhod.237297 1 atıf (OpenAlex) Kaynak: OpenAlex

Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings

International Journal of Infectious Diseases, 2023

DOI 10.1016/j.ijid.2023.10.013 PMID 37863310 16 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Predicting the next pandemic: VACCELERATE ranking of the World Health Organization's Blueprint for Action to Prevent Epidemics

Travel Medicine and Infectious Disease, 2023

DOI 10.1016/j.tmaid.2023.102676 PMID 38061408 35 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study

The Lancet Haematology, 2023

DOI 10.1016/s2352-3026(23)00207-7 PMID 37914483 15 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry

Therapeutic Advances in Hematology, 2023

DOI 10.1177/20406207231154706 PMID 36923264 9 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

Prognostic Significance of Monoclonal Paraproteinemia in Marginal Zone Lymphoma

Blood, 2023

DOI 10.1182/blood-2023-186121 Açık erişimli tam metinKaynak: OpenAlex

Extracorporeal photopheresis in the treatment of acute and chronic graft-versus-host disease: A position statement from the Turkish Society of Apheresis (TSA)

Transfusion and Apheresis Science, 2022

DOI 10.1016/j.transci.2022.103373 PMID 35123893 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

Prospective registry of adult patients receiving therapeutic plasma exchange with a presumptive diagnosis of thrombotic microangiopathy (TMA): the Turkish hematology research and education group (ThREG)-TMA02 study

Transfusion and Apheresis Science, 2022

DOI 10.1016/j.transci.2022.103365 PMID 35120823 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

P-278: Post-authorization safety of lenalidomide + dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey

Clinical Lymphoma Myeloma & Leukemia, 2022

DOI 10.1016/s2152-2650(22)00608-5 Kaynak: OpenAlex

Real-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG),Non-kutanöz Periferik T-hücreli Lenfomalarda Klinik Özellikler ve Tedavi Sonuçlarına ilişkin Gerçek Yaşam Deneyimi:Türk Hematoloji Araştırma ve Eğitim Grubunun Çok Merkezli Çalışması

Turkish Journal of Hematology, 2022

DOI 10.4274/tjh.galenos.2022.2022.0052 PMID 35678126 Açık erişimli tam metinKaynak: ORCID

Assessment of relation between JAK2 gene and thrombosis in myeloproliferative neoplasms

Turkish Journal of Internal Medicine, 2022

DOI 10.46310/tjim.1055305 Açık erişimli tam metinKaynak: ORCID

COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey

Blood Advances, 2022

DOI 10.1182/bloodadvances.2022007357 PMID 35500220 10 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Evaluation of Platelet Transfusions Practice: Results of at a Tertiary Healthcare Center in Turkey

Harran Üniversitesi Tıp Fakültesi Dergisi, 2022

DOI 10.35440/hutfd.1066407 Açık erişimli tam metinKaynak: ORCID

Berlin-Frankfurt-Munster (BFM) versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone (Hyper-CVAD) chemotherapy regimens in Adult T-Cell ALL and Adolescent and Young Adult (AYA) Patients

Eurasian Journal of Medical Advances, 2022

DOI 10.14744/ejma.2022.70299 Açık erişimli tam metinKaynak: ORCID

Assessment of Bone Marrow Biopsy and Cytogenetic Findings in Patients with Multiple Myeloma

Turkish journal of haematology : official journal of Turkish Society of Haematology, 2022

DOI 10.4274/tjh.galenos.2021.2021.0325 PMID 34823323 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: Europe PMC

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Blood, 2022

DOI 10.1182/blood.2022017257 PMID 36126318 75 atıf (Europe PMC) Açık erişimli tam metinKaynak: Europe PMC

Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

Cancers, 2022

DOI 10.3390/cancers14225530 PMID 36428621 10 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

Haematologica, 2022

DOI 10.3324/haematol.2021.279012 PMID 35021599 133 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)

Haematologica, 2022

DOI 10.3324/haematol.2022.280847 PMID 35545919 53 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies

Leukemia & lymphoma/Leukemia and lymphoma, 2022

DOI 10.1080/10428194.2021.2020779 PMID 35014928 14 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

Granulocytic sarcoma with unusual localizations (breast and stomach) without bone marrow involvement after the allogeneic transplantation

Journal of Clinical Images and Medical Case Reports, 2022

DOI 10.52768/2766-7820/1582 Açık erişimli tam metinKaynak: OpenAlex

PB2181: DOES SARCOPENIA INFLUENCE THE SUCCESS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION?

HemaSphere, 2022

DOI 10.1097/01.hs9.0000851552.93330.58 Açık erişimli tam metinKaynak: OpenAlex

P-166: Free light chain escape: should we monitor free light chains more closely?

Clinical Lymphoma Myeloma & Leukemia, 2022

DOI 10.1016/s2152-2650(22)00496-7 Kaynak: OpenAlex